Diversify Wealth Management LLC Buys 4,933 Shares of Repligen Corporation $RGEN

Diversify Wealth Management LLC increased its stake in Repligen Corporation (NASDAQ:RGEN) by 56.8% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 13,616 shares of the biotechnology company’s stock after acquiring an additional 4,933 shares during the period. Diversify Wealth Management LLC’s holdings in Repligen were worth $1,540,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD raised its position in Repligen by 31.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company’s stock valued at $753,603,000 after purchasing an additional 1,091,683 shares in the last quarter. United Capital Financial Advisors LLC purchased a new position in shares of Repligen in the 3rd quarter worth about $368,387,000. Opti Capital Management LP purchased a new position in shares of Repligen in the 4th quarter worth about $2,399,209,000. Invesco Ltd. increased its position in shares of Repligen by 43.9% during the 4th quarter. Invesco Ltd. now owns 1,256,439 shares of the biotechnology company’s stock valued at $205,880,000 after purchasing an additional 383,399 shares during the last quarter. Finally, Wasatch Advisors LP bought a new position in shares of Repligen during the 1st quarter valued at about $146,513,000. Institutional investors own 97.64% of the company’s stock.

Insider Buying and Selling at Repligen

In other news, CFO Jason K. Garland sold 733 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the transaction, the chief financial officer owned 19,359 shares in the company, valued at approximately $2,807,055. This trade represents a 3.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.60% of the company’s stock.

Repligen Trading Up 1.6%

NASDAQ RGEN opened at $147.13 on Wednesday. The firm has a market cap of $8.30 billion, a PE ratio of 163.48, a price-to-earnings-growth ratio of 2.79 and a beta of 1.06. Repligen Corporation has a 1-year low of $100.99 and a 1-year high of $175.77. The stock has a 50-day moving average of $127.32 and a 200-day moving average of $133.67. The company has a current ratio of 9.20, a quick ratio of 7.78 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.10. The business had revenue of $194.25 million for the quarter, compared to analyst estimates of $192.05 million. Repligen had a return on equity of 4.88% and a net margin of 6.73%.Repligen’s revenue for the quarter was up 14.8% compared to the same quarter last year. During the same period last year, the company earned $0.39 EPS. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, sell-side analysts forecast that Repligen Corporation will post 1.99 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. Wolfe Research started coverage on Repligen in a report on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 price objective on the stock. Benchmark raised Repligen from a “hold” rating to a “buy” rating and set a $185.00 target price for the company in a research note on Tuesday, July 7th. Citigroup upgraded shares of Repligen to a “buy” rating in a research report on Tuesday, July 7th. HSBC decreased their price target on shares of Repligen from $170.00 to $150.00 and set a “buy” rating on the stock in a research note on Wednesday, June 3rd. Finally, Weiss Ratings lowered shares of Repligen from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, June 26th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Repligen presently has an average rating of “Moderate Buy” and a consensus target price of $165.00.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.